BioAlliance wins US patent for Sitavig tablet
BioAlliance has developed Sitavig (mucoadhesive tablet containing acyclovir) for the treatment of labial herpes in immunocompetent patients presenting more than four episodes a year. The mucoadhesive tablet should
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.